Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis.

biomarkers interstitial lung disease prognosis systemic sclerosis

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Aug 2022
Historique:
received: 04 07 2022
revised: 24 08 2022
accepted: 26 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 10 9 2022
Statut: epublish

Résumé

(1) Background: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease with a high mortality and morbidity rate. Identification of biomarkers that can predict the evolution of SSc is a key factor in the management of patients. The aim of this study was to assess the association of routine laboratory parameters, widely used in practice and easily available, with the severity and progression of SSc. (2) Methods: In this retrospective monocentric cohort study, 372 SSc patients were included. We gathered clinical and laboratory data including routine laboratory parameters: C-reactive-protein (CRP), erythrocyte sedimentation rate (ESR), complete blood count, serum sodium and potassium levels, creatinin, urea, ferritin, albumin, uric acid, N-terminal pro-brain natriuretic peptide (NTproBNP), serum protein electrophoresis, and liver enzymes. Associations between these routine laboratory parameters and clinical presentation and outcome were assessed. (3) Results: Median (interquartile range) age was 59.0 (50.0; 68.0) years. White blood cell, monocyte, and neutrophil absolute counts were significantly higher in patients with diffuse cutaneous SSc and with interstitial lung disease (ILD) (p < 0.001). CRP was significantly higher in patients with ILD (p < 0.001). Hemoglobin and ferritin were significantly lower in patients with pulmonary hypertension (PH) including pulmonary arterial hypertension and ILD associated PH (p = 0.016 and 0.046, respectively). Uric acid and NT pro BNP were significantly higher in patients with PH (<0.001). Monocyte count was associated with ILD progression over time. (4) Conclusions: Overall, our study highlights the association of routine laboratory parameters used in current practice with the severity and progression of SSc.

Identifiants

pubmed: 36079017
pii: jcm11175087
doi: 10.3390/jcm11175087
pmc: PMC9457158
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Rheumatol. 2019 Feb;46(2):176-183
pubmed: 30275260
Arthritis Care Res (Hoboken). 2022 Mar 14;:
pubmed: 35287250
Acta Dermatovenerol Alp Pannonica Adriat. 2020 Sep;29(3):101-107
pubmed: 32975295
Pulm Circ. 2019 Jul 29;9(3):2045894019859477
pubmed: 31384431
Semin Respir Crit Care Med. 2014 Apr;35(2):213-21
pubmed: 24668536
Nat Rev Rheumatol. 2018 Sep;14(9):511-527
pubmed: 30111804
J Clin Med. 2020 Oct 22;9(11):
pubmed: 33105647
Curr Opin Rheumatol. 2019 Nov;31(6):595-602
pubmed: 31436584
Respir Res. 2018 Sep 24;19(1):186
pubmed: 30249259
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Ann Rheum Dis. 2019 Sep;78(9):1242-1248
pubmed: 31227488
Eur Respir J. 2020 May 14;55(5):
pubmed: 32079645
Rheumatology (Oxford). 2012 Jun;51(6):1017-26
pubmed: 21900368
Intern Emerg Med. 2020 Jun;15(4):573-585
pubmed: 32040829
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1375-80
pubmed: 23401350
Arthritis Rheum. 2008 Jan;58(1):284-91
pubmed: 18163505
Biomed Res Int. 2019 Jan 23;2019:4569826
pubmed: 30809542
Blood. 2008 Feb 15;111(4):2392-9
pubmed: 18073346
Clin Rheumatol. 2020 Jan;39(1):227-232
pubmed: 31734774
Acta Cardiol. 2021 Apr;76(2):162-167
pubmed: 31902301
Ann Rheum Dis. 2017 Jan;76(1):270-276
pubmed: 27621285
Rheumatology (Oxford). 2014 Feb;53(2):285-92
pubmed: 24155365
Clin Rheumatol. 2018 Apr;37(4):987-997
pubmed: 29196890
J Rheumatol. 2013 Apr;40(4):435-46
pubmed: 23378460
Expert Rev Clin Immunol. 2019 Nov;15(11):1215-1223
pubmed: 31539483
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1405-14
pubmed: 22556030
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
J Dermatol. 2016 Jan;43(1):29-38
pubmed: 26782004
Clin Rheumatol. 2020 Jan;39(1):77-83
pubmed: 31317426
Respir Med. 2003 Feb;97(2):130-3
pubmed: 12587962
Arthritis Res Ther. 2020 Feb 18;22(1):30
pubmed: 32070422
Ann Rheum Dis. 2021 Feb;80(2):219-227
pubmed: 32988845
Arthritis Res Ther. 2019 Apr 3;21(1):86
pubmed: 30944015
Arthritis Rheumatol. 2021 Jun;73(6):1005-1013
pubmed: 33350170
Eur Respir J. 2021 Aug 5;58(2):
pubmed: 33446602
Cytokine. 2020 Aug;132:154635
pubmed: 30685202
Respir Res. 2021 May 5;22(1):140
pubmed: 33952261
Rheumatology (Oxford). 2019 Sep 1;58(9):1534-1546
pubmed: 31292645
Front Med (Lausanne). 2018 Jun 06;5:175
pubmed: 29928643
Clin Rheumatol. 2017 Jul;36(7):1649-1654
pubmed: 28293753

Auteurs

Liticia Chikhoune (L)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Thierry Brousseau (T)

CHU Lille, Service de Biochimie Automatisée Protéines, F-59000 Lille, France.

Sandrine Morell-Dubois (S)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Meryem Maud Farhat (MM)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

Helene Maillard (H)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Emmanuel Ledoult (E)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

Marc Lambert (M)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Cecile Yelnik (C)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Sebastien Sanges (S)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

Vincent Sobanski (V)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

Eric Hachulla (E)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

David Launay (D)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, F-59000 Lille, France.
Inserm, F-59000 Lille, France.

Classifications MeSH